Alnylam Pharmaceuticals
ALNY
#584
Rank
NZ$56.83 B
Marketcap
$442.69
Share price
-0.89%
Change (1 day)
49.62%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total liabilities

Total liabilities on the balance sheet as of June 2024 : NZ$6.48 B

According to Alnylam Pharmaceuticals 's latest financial reports the company's total liabilities are NZ$6.48 B. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Alnylam Pharmaceuticals - Total liabilities on balance sheet (from 2003 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31NZ$6.40 B9.77%
2022-12-31NZ$5.83 B30.8%
2021-12-31NZ$4.46 B34.2%
2020-12-31NZ$3.32 B134.46%
2019-12-31NZ$1.41 B248.74%
2018-12-31NZ$0.40 B26.48%
2017-12-31NZ$0.32 B-35%
2016-12-31NZ$0.49 B177.61%
2015-12-31NZ$0.17 B-2.49%
2014-12-31NZ$0.18 B-0.09%
2013-12-31NZ$0.18 B-2.31%
2012-12-31NZ$0.18 B-10.87%
2011-12-31NZ$0.21 B-31.33%
2010-12-31NZ$0.30 B-27.32%
2009-12-31NZ$0.42 B-31.14%
2008-12-31NZ$0.61 B60.28%
2007-12-31NZ$0.38 B591.75%
2006-12-31NZ$55.11 M3.02%
2005-12-31NZ$53.5 M91.22%
2004-12-31NZ$27.97 M-70.61%
2003-12-31NZ$95.2 M140.05%
2002-12-31NZ$39.66 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
NZ$0.88 B-86.42%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$12.73 B 96.40%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$3.79 B-41.51%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.94 B-85.43%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$9.59 M-99.85%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$89.87 B 1,285.68%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NZ$98.34 B 1,416.28%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$56.20 B 766.62%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel